Akcea Therapeutics (NASDAQ:AKCA) and majority owner Ionis Pharmaceuticals (NASDAQ:IONS) announce positive results from a Phase 2 clinical trial evaluating antisense oligonucleotide AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
The study met the primary endpoint of significant
triglyceride lowering and multiple secondary endpoints with a favorable
safety and tolerability profile.
There were statistically significant dose-dependent reductions in fasting triglycerides at all dose levels compared to placebo.
There were dose-dependent reductions in ANGPTL3,
apoC-III, very low-density lipoprotein (VLDL-C), non-HDL cholesterol and
total cholesterol compared to placebo.
No reductions were observed in liver fat or HbA1C levels versus placebo.
Detailed results will be submitted for presentation at a future medical conference.
https://seekingalpha.com/news/3535413-akcea-therapeutics-up-6-after-hours-on-positive-akcea-angptl3-lrx-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.